Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial

17 Apr 2024

Abstract excerpt

INTRODUCTION: In trials of amyloid-lowering drugs for Alzheimer's disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emission tomography (PET) amyloid eligibility for the ongoing AHEAD Study preclinical AD program (NCT04468659). METHODS: Univariate logistic regression models were used to examine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Schizophrenia research and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38629508
DOI: 10.1002/alz.13803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialPMID 38629508Read ↗

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read ↗

Racial and Ethnic Reporting and Representation in Phase III Alzheimer’s Disease Clinical Trials in the USSemantic proximity Read ↗

Why Inclusion Matters for Alzheimer’s Disease Biomarker Discovery in PlasmaSemantic proximity Read ↗

Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individualsSemantic proximity Read ↗

Equity and Transportability of Plasma ATN Phenotypes in a Population-Representative U.S. Aging CohortSemantic proximity Read ↗

Baseline levels and longitudinal rates of change in plasma Aβ42/40 among self-identified Black/African American and White individualsSemantic proximity Read ↗

The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE.Semantic proximity Read ↗

Assessment of Racial Disparities in Biomarkers for Alzheimer DiseaseSemantic proximity Read ↗

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read ↗

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.Semantic proximity Read ↗

A Systematic Review of Representation in Clinical Trials for Transthyretin Associated Cardiac Amyloidosis: Where Demographics Diverge from DiseaseSemantic proximity Read ↗

Alzheimer's disease plasma biomarkers and physical functioning in a diverse sample of adultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.